On October 16, 2018, Shu, Xiaohong; Chi, Fuyun; Yang, Song; Ma, Xiaodong; Li, Chuangang; Li, Hong; Wu, Moli; Zhen, Yuhong; Diao, Yunpeng; Song, Danyang; Li, Hui; Jin, Junmei published a patent.HPLC of Formula: 16230-24-3 The title of the patent was Thiopyrimidine heterocyclic antitumor compound and preparation method and its use. And the patent contained the following:
A thiopyrimidine heterocyclic antitumor compound for the treatment of small cell lung cancer, non-small cell lung cancer, EGFR-T790M mutant non-small cell lung cancer is provided. The compound is represented by the formula I, or a pharmaceutically acceptable salt thereof, which inhibits wild-type EGFR, mutant EGFR-T790M epidermal factor receptor protein tyrosine kinase, where X is O or NH; M is S(O)n; n is 0 or 1; R is alkyl-morpholine. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).HPLC of Formula: 16230-24-3
The Article related to thiopyrimidine heterocyclic antitumor, Heterocyclic Compounds (More Than One Hetero Atom): Oxazines (Including Morpholine) and other aspects.HPLC of Formula: 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics